Search

Author/Creator Krop, Ian E

1. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Issue 3 (March 2023)

Authors:
Tolaney, Sara M; Tarantino, Paolo; Graham, Noah; Tayob, Nabihah; Parè, Laia; Villacampa, Guillermo; Dang, Chau T; Yardley, Denise A; Moy, Beverly; Marcom, P Kelly; Albain, Kathy S; Rugo, Hope S; Ellis, Matthew J; Shapira, Iuliana; Wolff, Antonio C; Carey, Lisa A; Barroso-Sousa, Romualdo; Villagra...
Journal:
Lancet oncology
Issue:
Volume 24:Issue 3(2023)
Page Start:
273
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Personalization of loco-regional care for primary breast cancer patients (part 1). (May 2015)

Authors:
Toi, Masakazu; Winer, Eric P; Benson, John R; Inamoto, Takashi; Forbes, John F; von Minckwitz, Gunter; Robertson, John FR; Grobmyer, Stephen R; Jatoi, Ismail; Sasano, Hironobu; Kunkler, Ian; Ho, Alice Y; Yamauchi, Chikako; Chow, Louis WC; Huang, Chiun-Sheng; Han, Wonshik; Noguchi, Shinzaburo; Peg...
Journal:
Future oncology
Issue:
Volume 11:Number 9(2015)
Page Start:
1297
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Personalization of loco-regional care for primary breast cancer patients (part 2). (May 2015)

Authors:
Toi, Masakazu; Winer, Eric P; Benson, John R; Inamoto, Takashi; Forbes, John F; von Minckwitz, Gunter; Robertson, John FR; Grobmyer, Stephen R; Jatoi, Ismail; Sasano, Hironobu; Kunkler, Ian; Ho, Alice Y; Yamauchi, Chikako; Chow, Louis WC; Huang, Chiun-Sheng; Han, Wonshik; Noguchi, Shinzaburo; Peg...
Journal:
Future oncology
Issue:
Volume 11:Number 9(2015)
Page Start:
1301
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Issue 10 (17th October 2022)

Authors:
Waks, Adrienne G; Keenan, Tanya E; Li, Tianyu; Tayob, Nabihah; Wulf, Gerburg M; Richardson, Edward T; Attaya, Victoria; Anderson, Leilani; Mittendorf, Elizabeth A; Overmoyer, Beth; Winer, Eric P; Krop, Ian E; Agudo, Judith; Van Allen, Eliezer M; Tolaney, Sara M
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 10(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 6 (June 2016)

Authors:
Krop, Ian E; Mayer, Ingrid A; Ganju, Vinod; Dickler, Maura; Johnston, Stephen; Morales, Serafin; Yardley, Denise A; Melichar, Bohuslav; Forero-Torres, Andres; Lee, Soo Chin; de Boer, Richard; Petrakova, Katarina; Vallentin, Susanne; Perez, Edith A; Piccart, Martine; Ellis, Matthew; Winer, Eric; G...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 6(2016:Jun.)
Page Start:
811
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Issue 6 (June 2019)

Authors:
Tamura, Kenji; Tsurutani, Junji; Takahashi, Shunji; Iwata, Hiroji; Krop, Ian E; Redfern, Charles; Sagara, Yasuaki; Doi, Toshihiko; Park, Haeseong; Murthy, Rashmi K; Redman, Rebecca A; Jikoh, Takahiro; Lee, Caleb; Sugihara, Masahiro; Shahidi, Javad; Yver, Antoine; Modi, Shanu
Journal:
Lancet oncology
Issue:
Volume 20:Issue 6(2019)
Page Start:
816
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Issue 6 (June 2017)

Authors:
Diéras, Véronique; Miles, David; Verma, Sunil; Pegram, Mark; Welslau, Manfred; Baselga, José; Krop, Ian E; Blackwell, Kim; Hoersch, Silke; Xu, Jin; Green, Marjorie; Gianni, Luca
Journal:
Lancet oncology
Issue:
Volume 18:Issue 6(2017:Jun.)
Page Start:
732
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Issue 6 (June 2017)

Authors:
Krop, Ian E; Kim, Sung-Bae; Martin, Antonio Gonzalez; LoRusso, Patricia M; Ferrero, Jean-Marc; Badovinac-Crnjevic, Tanja; Hoersch, Silke; Smitt, Melanie; Wildiers, Hans
Journal:
Lancet oncology
Issue:
Volume 18:Issue 6(2017:Jun.)
Page Start:
743
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗